FR3000896B1 - Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil - Google Patents

Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil

Info

Publication number
FR3000896B1
FR3000896B1 FR1350308A FR1350308A FR3000896B1 FR 3000896 B1 FR3000896 B1 FR 3000896B1 FR 1350308 A FR1350308 A FR 1350308A FR 1350308 A FR1350308 A FR 1350308A FR 3000896 B1 FR3000896 B1 FR 3000896B1
Authority
FR
France
Prior art keywords
sleep
administration
treatment
active ingredient
galenic form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1350308A
Other languages
English (en)
Other versions
FR3000896A1 (fr
Inventor
Philippe Perovitch
Jack Auzerie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ROSSELLO RAPHAEL
Original Assignee
ROSSELLO RAPHAEL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1350308A priority Critical patent/FR3000896B1/fr
Application filed by ROSSELLO RAPHAEL filed Critical ROSSELLO RAPHAEL
Priority to JP2015552133A priority patent/JP2016504405A/ja
Priority to MX2015009027A priority patent/MX2015009027A/es
Priority to CA2897685A priority patent/CA2897685A1/fr
Priority to CN201480011684.3A priority patent/CN105025880A/zh
Priority to RU2015134148A priority patent/RU2015134148A/ru
Priority to EP14703148.8A priority patent/EP2943182A1/fr
Priority to PCT/FR2014/050070 priority patent/WO2014108657A1/fr
Priority to US14/759,822 priority patent/US20150352038A1/en
Priority to BR112015016869A priority patent/BR112015016869A2/pt
Publication of FR3000896A1 publication Critical patent/FR3000896A1/fr
Application granted granted Critical
Publication of FR3000896B1 publication Critical patent/FR3000896B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR1350308A 2013-01-14 2013-01-14 Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil Expired - Fee Related FR3000896B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1350308A FR3000896B1 (fr) 2013-01-14 2013-01-14 Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
US14/759,822 US20150352038A1 (en) 2013-01-14 2014-01-14 A dosage form for administering an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder
CA2897685A CA2897685A1 (fr) 2013-01-14 2014-01-14 Forme galenique pour l'administration d'un principe actif
CN201480011684.3A CN105025880A (zh) 2013-01-14 2014-01-14 用于施用活性成分的盖仑氏形式
RU2015134148A RU2015134148A (ru) 2013-01-14 2014-01-14 Галеновая форма для введения активного действующего вещества
EP14703148.8A EP2943182A1 (fr) 2013-01-14 2014-01-14 Forme galenique pour l'administration d'un principe actif
JP2015552133A JP2016504405A (ja) 2013-01-14 2014-01-14 ガレヌス製剤の有効成分の投与剤形
MX2015009027A MX2015009027A (es) 2013-01-14 2014-01-14 Forma galenica para la administracion de un principio activo.
BR112015016869A BR112015016869A2 (pt) 2013-01-14 2014-01-14 forma de dosagem para a administração de um princípio ativo para indução acelerada do sono e/ou para o tratamento de distúrbios do sono e/ou para tratar um distúrbio do sistema nervoso central
PCT/FR2014/050070 WO2014108657A1 (fr) 2013-01-14 2014-01-14 Forme galenique pour l'administration d'un principe actif

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1350308A FR3000896B1 (fr) 2013-01-14 2013-01-14 Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil

Publications (2)

Publication Number Publication Date
FR3000896A1 FR3000896A1 (fr) 2014-07-18
FR3000896B1 true FR3000896B1 (fr) 2016-08-26

Family

ID=48170667

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1350308A Expired - Fee Related FR3000896B1 (fr) 2013-01-14 2013-01-14 Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil

Country Status (10)

Country Link
US (1) US20150352038A1 (fr)
EP (1) EP2943182A1 (fr)
JP (1) JP2016504405A (fr)
CN (1) CN105025880A (fr)
BR (1) BR112015016869A2 (fr)
CA (1) CA2897685A1 (fr)
FR (1) FR3000896B1 (fr)
MX (1) MX2015009027A (fr)
RU (1) RU2015134148A (fr)
WO (1) WO2014108657A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3031668A1 (fr) 2015-01-20 2016-07-22 Philippe Perovitch Dispositif d'administration d'un principe actif par voie per-muqueuse buccale.
EP3337480A4 (fr) 2015-08-17 2019-05-08 Aequus Pharmaceuticals Inc. Administration transdermique de succinate de doxylamine et de chlorhydrate de piridoxine
RU2620855C1 (ru) * 2016-02-18 2017-05-30 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для профилактики и лечения нарушений сна
FR3053244A1 (fr) 2016-07-01 2018-01-05 Philippe Perovitch Dispositif d'administration d'au moins un principe actif par voie per-muqueuse buccale.
US20210113456A1 (en) * 2017-07-13 2021-04-22 Maxinase Life Sciences Limited Pharmaceutical compositions of ramelteon and methods of use thereof
WO2021258326A1 (fr) * 2020-06-24 2021-12-30 中国人民解放军军事科学院军事医学研究院 Application de nanocristaux de midazolam dans la préparation d'un médicament destiné à améliorer la perméabilité de la barrière hémato-encéphalique

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229490T2 (de) 1991-05-09 2000-02-17 Neurim Pharmaceuticals (1991) Ltd., Tel Aviv Melatonin enthaltende Arzneimittel
FR2754454B1 (fr) 1996-10-10 1998-11-27 Oreal Utilisation d'au moins un glycol comme agent de solubilisation de la melatonine dans l'eau et compositions obtenues
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20050163719A1 (en) 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
IL130171A (en) 1999-05-27 2004-06-01 Neurim Pharma 1991 Melatonin for use in the prevention and treatment of tardive dyskinesia, pharmaceutical formulations comprising it and its use for the manufacture of medicaments
KR20070030178A (ko) * 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
EP2767163A1 (fr) * 2005-02-17 2014-08-20 Abbott Laboratories Administration par voie transmuqueuse de compositions médicamenteuses pour le traitement et la prévention de troubles chez les animaux
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
ZA200710205B (en) * 2005-05-25 2009-03-25 Transcept Pharmaceuticals Inc Solid compositions and methods for treating middle-of-the night insomnia
FR2894475B1 (fr) * 2005-12-14 2008-05-16 Servier Lab Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine
KR20070079792A (ko) 2006-02-03 2007-08-08 삼성전자주식회사 디스크리트 타임 발진기를 이용한 모터 구동회로와 그 방법
ITRM20060108A1 (it) 2006-03-03 2007-09-04 Colella Gino Composizioni a base di melatonina e sostanze immunostimolanti
EP2015632B1 (fr) 2006-04-19 2015-12-02 Mist Pharmaceuticals, LLC Formulations hydroalcooliques stables à pulvériser dans la cavité buccale et procédés associés
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
FR2910317B1 (fr) * 2006-12-21 2009-02-13 Philippe Perovitch Forme galenique pour l'administration par voie transmuqueuse de paracetamol
EP2114384A4 (fr) * 2007-02-15 2012-02-01 Derma Young Ltd Compositions et méthodes permettant d'améliorer l'administration transmuqueuse
WO2008141264A1 (fr) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Compositions et procédés anti-insomnie
FR2918874B1 (fr) 2007-07-20 2009-10-09 Philippe Perovitch Dispositif de conditionnement et d'administration sub-linguale de principes actifs
WO2009021106A1 (fr) * 2007-08-07 2009-02-12 Acelrx Pharmaceuticals, Inc. Compositions et procédés de sédation et d'analgésie procédurales utilisant les formes posologiques transmucosales orales
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
FR2930140B1 (fr) 2008-04-17 2011-04-22 Philippe Perovitch Dispositif pour la conservation, la preparation extemporanee et l'administration d'un faible dosage de principe actif
FR2939321B1 (fr) 2008-12-05 2011-08-26 Philippe Perovitch Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique.
FR2940116B1 (fr) * 2008-12-22 2012-07-06 Philippe Perovitch Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale
FR2940911B1 (fr) * 2009-01-13 2012-09-21 Philippe Perovitch Formulation pour l'administration par voie trans-muqueuse buccale de molecules antalgiques et/ou anti-spasmodiques
FR2947729B1 (fr) * 2009-07-10 2012-01-20 Philippe Perovitch Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale

Also Published As

Publication number Publication date
EP2943182A1 (fr) 2015-11-18
FR3000896A1 (fr) 2014-07-18
MX2015009027A (es) 2016-01-20
WO2014108657A1 (fr) 2014-07-17
RU2015134148A (ru) 2017-02-16
US20150352038A1 (en) 2015-12-10
BR112015016869A2 (pt) 2017-07-11
JP2016504405A (ja) 2016-02-12
CN105025880A (zh) 2015-11-04
CA2897685A1 (fr) 2014-07-17

Similar Documents

Publication Publication Date Title
EP2914277A4 (fr) Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres
EP2911664A4 (fr) Polythérapies pour le traitement de la maladie d'alzheimer et des troubles associés
EP2970099A4 (fr) Dérivés de 3-phénylpropylamine substitués pour le traitement des maladies et des troubles ophtalmiques
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP2830646A4 (fr) Compositions et méthodes d'utilisation pour le traitement de troubles métaboliques
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
EP2827856A4 (fr) Composés et compositions pour le traitement d'affections musculaires
EP3307754A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles de la peau
EP2983619A4 (fr) Logiciel d'orientation et de planification chirurgicales pour le traitement de l'astigmatisme
EP2810599A4 (fr) Méthode et système d'électrostimulation pour le traitement de l'apnée du sommeil
EP2691102A4 (fr) Composition d'herbes pour le traitement de maladies neurologiques et l'amélioration des troubles de la mémoire
MA47069A (fr) Formes pharmaceutiques contenant des inhibiteurs des canaux task-1 et task-3 et leur utilisation pour le traitement de troubles respiratoires
CO7141411A2 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas
EP3270914C0 (fr) Composés et formes de traitement des troubles sexuels chez la femme
EP2827847A4 (fr) Complexes contenant du strontium administré par voie topique pour le traitement de la douleur, du prurit et de l'inflammation
EP2928477A4 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
EP2812030A4 (fr) Vaccin associant un antigène et un adn pour la prévention et le traitement d'une infection par un vrs
EP1848270A4 (fr) Administration par voie transmuqueuse de compositions medicamenteuses pour le traitement et la prevention de troubles chez les animaux
EP3291693A4 (fr) Régime alimentaire imitant et favorisant le jeûne pour le traitement de l'hypertension et des troubles lipidiques
MA47074A (fr) Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires
EP2827863A4 (fr) Méthode de traitement des états réagissant à la bendamustine chez des patients nécessitant des volumes réduits pour l'administration
EP2999444A4 (fr) Système thérapeutique transdermique pour dosage à libération prolongée de pramipexole dans le traitement de troubles neurologiques
EP2819741A4 (fr) Implants de médicaments solides pour l'administration intracochléaire d'agents thérapeutiques pour le traitement de troubles otiques
EP2890370A4 (fr) Agents utiles pour le traitement de l'obésité, du diabète et de troubles associés
EP2849787A4 (fr) Antagonistes de lingo-2 pour le traitement d'affections impliquant des neurones moteurs

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20190906